Combination with dendritic cell vaccine therapy and cryoablation for lung cancers

Combination with dendritic cell vaccine therapy and cryoablation for lung cancers - Combination with dendritic cell vaccine therapy and cryoablation for lung cancers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059855

Enrollment

100

Registered

2025-11-22

Start date

2025-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pulmonary tumor

Interventions

Treatment period is 3 months. Dendritic cells are extracted from the patient, which are incubated with cancer antigen or cytokine to strengthen the immunity. Every 2-3 weeks, dendritic cells are injec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient has multiple metastases, of which one exists in lung and its size is over 2 cm. The patient has been already treated by chemotherapy, of which effect is stable or progressive disease. The patient performance status is lower than 2.

Exclusion criteria

Exclusion criteria: Myelodysplastic syndromes. Severe clinical symptoms. Psychiatric disorders. Immunocompromised disease. Pregnant or breast-feeding woman. Unsuitable status judged by doctor in charge.

Design outcomes

Primary

Measure	Time frame
Shrinking effect of metastases without cryoablation and survival time.	—

Secondary

Measure	Time frame
Complication of the combination therapy	—

Countries

Japan

Contacts

Public ContactHiroaki Nomori

Kashiwa Kousei General Hospital Thoracic Surgery

hnomori@qk9.so-net.ne.jp0471451111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026